Biotechnology · La Jolla, California, United States
$0.95
+5.60% (+$0.05)2026-07-09
Smart-Money SignalNeutral · 54/100— Insiders are net buyers over 90 days ($1.4M, 5 buys vs 0 sales)
Net Income-$7.8M
EPS$-1.28
Market Cap$13.6M
Price Performance
Historical data including institutional events
Company Profile
A
A. Leheny
CEO & Executive Director
CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage.
Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.
The company also develops Auxora for the treatment of ulcerative colitis, traumatic brain injury, and allergic asthma; and oral CRAC channel inhibitors for use in chronic inflammatory and immunologic disease.
The company is based in La Jolla, California.
